Data from Investigator-Sponsored Phase 2 Study of Calitheraa??s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from an investigator-sponsored trial evaluating telaglenastat (CB-839) in combination with azacitidine will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting 2019 taking place December 7-10, in Orlando, Florida.
a??Telaglenastat is being evaluated in multiple tumor types through investigator-sponsored trials, and we are excited to see progress as data from these trials are beginning to be presented at prestigious conferences such as ASH,a?? said Susan Molineaux, PhD, president and chief executive officer of Calithera. a??We are grateful to the patients and clinicians who are participating in all trials evaluating glutaminase inhibition as a novel approach to the treatment of cancer, and we continue to observe through these trials the potential of telaglenastat in a wide range of cancer indications.a??Presentation details: Date: Monday, December 9 at 7:30 a.m. Eastern TimeTitle: Interim Analysis of Phase 2 Study of Telaglenastat in combination with Azacitidine in Myelodysplastic Syndrome
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июнь 2020    »